Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
[Display omitted] Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 mo...
Gespeichert in:
| Veröffentlicht in: | Mucosal immunology 2024-04, Vol.17 (2), p.201-210 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 210 |
|---|---|
| container_issue | 2 |
| container_start_page | 201 |
| container_title | Mucosal immunology |
| container_volume | 17 |
| creator | Nantel, Sabryna Sheikh-Mohamed, Salma Chao, Gary Y.C. Kurtesi, Alexandra Hu, Queenie Wood, Heidi Colwill, Karen Li, Zhijie Liu, Ying Seifried, Laurie Bourdin, Benoîte McGeer, Allison Hardy, William R. Rojas, Olga L. Al-Aubodah, Tho-Alfakar Liu, Zhiyang Ostrowski, Mario A. Brockman, Mark A. Piccirillo, Ciriaco A. Quach, Caroline Rini, James M. Gingras, Anne-Claude Decaluwe, Hélène Gommerman, Jennifer L. |
| description | [Display omitted]
Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two-dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show thatBT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary immunoglobulin (Ig)G and IgA levels against the Omicron spike and enhanced reactivity to the ancestral spike for the IgA isotype, which also reacted with SARS-CoV-1. Serumneutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for the development of intranasal vaccines that could emulate the enhanced mucosal and humoral immunity induced by Omicron BT without exposing individuals to the risks associated with SARS-CoV-2 infection. |
| doi_str_mv | 10.1016/j.mucimm.2024.01.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2925485609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933021924000047</els_id><sourcerecordid>2925485609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-5dae5b623892cc8190cfa2266a8f72e2c73de1ba773b5e6e22eba7fd9eb041ca3</originalsourceid><addsrcrecordid>eNp9kcuO1DAQRS0EYh7wBwh5ySbBj9hJNkijFo-RRhqJAbaW41RoN3Hc2HFL_S98LNX0wJKVy6VTvq57CXnFWc0Z1293dSjOh1ALJpqa8Zqx5gm55L1UlWyUfvqnlhUTvL8gVznvGNOMKfmcXMhOtF3D1SX5tYlhb5PPcaFxovfBu4TlkMD-WLcplu9b6pcJ3OqxfYCUS6YhLvFgZ1hW-nDz-aHaxG-VQGxNNpTsymwTHWLMKySa4AB2znT00wQJFgcZSYp_j9nO1C4jzUckUZhuS4gJm7hVWfx6fEGeTTgLLx_Pa_L1w_svm0_V3f3H283NXeWkFmulRgtq0EJ2vXCu4z1zkxVCa9tNrQDhWjkCH2zbykGBBiEAL9PYw8Aa7qy8Jm_O7-5T_Fkgryb47GCe7QKxZCN6oZpOadYj2pxRtCnnBJPZJx9sOhrOzCkXszPnXMwpF8O4wVxw7PWjQhkCjP-G_gaBwLszALjnwUMy2fmTW6NPaL4Zo_-_wm_WWaW-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2925485609</pqid></control><display><type>article</type><title>Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Nantel, Sabryna ; Sheikh-Mohamed, Salma ; Chao, Gary Y.C. ; Kurtesi, Alexandra ; Hu, Queenie ; Wood, Heidi ; Colwill, Karen ; Li, Zhijie ; Liu, Ying ; Seifried, Laurie ; Bourdin, Benoîte ; McGeer, Allison ; Hardy, William R. ; Rojas, Olga L. ; Al-Aubodah, Tho-Alfakar ; Liu, Zhiyang ; Ostrowski, Mario A. ; Brockman, Mark A. ; Piccirillo, Ciriaco A. ; Quach, Caroline ; Rini, James M. ; Gingras, Anne-Claude ; Decaluwe, Hélène ; Gommerman, Jennifer L.</creator><creatorcontrib>Nantel, Sabryna ; Sheikh-Mohamed, Salma ; Chao, Gary Y.C. ; Kurtesi, Alexandra ; Hu, Queenie ; Wood, Heidi ; Colwill, Karen ; Li, Zhijie ; Liu, Ying ; Seifried, Laurie ; Bourdin, Benoîte ; McGeer, Allison ; Hardy, William R. ; Rojas, Olga L. ; Al-Aubodah, Tho-Alfakar ; Liu, Zhiyang ; Ostrowski, Mario A. ; Brockman, Mark A. ; Piccirillo, Ciriaco A. ; Quach, Caroline ; Rini, James M. ; Gingras, Anne-Claude ; Decaluwe, Hélène ; Gommerman, Jennifer L.</creatorcontrib><description>[Display omitted]
Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two-dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show thatBT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary immunoglobulin (Ig)G and IgA levels against the Omicron spike and enhanced reactivity to the ancestral spike for the IgA isotype, which also reacted with SARS-CoV-1. Serumneutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for the development of intranasal vaccines that could emulate the enhanced mucosal and humoral immunity induced by Omicron BT without exposing individuals to the risks associated with SARS-CoV-2 infection.</description><identifier>ISSN: 1933-0219</identifier><identifier>EISSN: 1935-3456</identifier><identifier>DOI: 10.1016/j.mucimm.2024.01.004</identifier><identifier>PMID: 38278415</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Mucosal immunology, 2024-04, Vol.17 (2), p.201-210</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-5dae5b623892cc8190cfa2266a8f72e2c73de1ba773b5e6e22eba7fd9eb041ca3</citedby><cites>FETCH-LOGICAL-c362t-5dae5b623892cc8190cfa2266a8f72e2c73de1ba773b5e6e22eba7fd9eb041ca3</cites><orcidid>0000-0002-1170-9475 ; 0000-0002-8979-1659 ; 0000-0002-7703-6779 ; 0009-0008-0436-9055 ; 0000-0001-6617-0633 ; 0000-0003-4576-6168 ; 0000-0002-4348-3159 ; 0000-0001-6432-1426 ; 0009-0008-0060-4716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38278415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nantel, Sabryna</creatorcontrib><creatorcontrib>Sheikh-Mohamed, Salma</creatorcontrib><creatorcontrib>Chao, Gary Y.C.</creatorcontrib><creatorcontrib>Kurtesi, Alexandra</creatorcontrib><creatorcontrib>Hu, Queenie</creatorcontrib><creatorcontrib>Wood, Heidi</creatorcontrib><creatorcontrib>Colwill, Karen</creatorcontrib><creatorcontrib>Li, Zhijie</creatorcontrib><creatorcontrib>Liu, Ying</creatorcontrib><creatorcontrib>Seifried, Laurie</creatorcontrib><creatorcontrib>Bourdin, Benoîte</creatorcontrib><creatorcontrib>McGeer, Allison</creatorcontrib><creatorcontrib>Hardy, William R.</creatorcontrib><creatorcontrib>Rojas, Olga L.</creatorcontrib><creatorcontrib>Al-Aubodah, Tho-Alfakar</creatorcontrib><creatorcontrib>Liu, Zhiyang</creatorcontrib><creatorcontrib>Ostrowski, Mario A.</creatorcontrib><creatorcontrib>Brockman, Mark A.</creatorcontrib><creatorcontrib>Piccirillo, Ciriaco A.</creatorcontrib><creatorcontrib>Quach, Caroline</creatorcontrib><creatorcontrib>Rini, James M.</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Decaluwe, Hélène</creatorcontrib><creatorcontrib>Gommerman, Jennifer L.</creatorcontrib><title>Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity</title><title>Mucosal immunology</title><addtitle>Mucosal Immunol</addtitle><description>[Display omitted]
Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two-dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show thatBT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary immunoglobulin (Ig)G and IgA levels against the Omicron spike and enhanced reactivity to the ancestral spike for the IgA isotype, which also reacted with SARS-CoV-1. Serumneutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for the development of intranasal vaccines that could emulate the enhanced mucosal and humoral immunity induced by Omicron BT without exposing individuals to the risks associated with SARS-CoV-2 infection.</description><issn>1933-0219</issn><issn>1935-3456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kcuO1DAQRS0EYh7wBwh5ySbBj9hJNkijFo-RRhqJAbaW41RoN3Hc2HFL_S98LNX0wJKVy6VTvq57CXnFWc0Z1293dSjOh1ALJpqa8Zqx5gm55L1UlWyUfvqnlhUTvL8gVznvGNOMKfmcXMhOtF3D1SX5tYlhb5PPcaFxovfBu4TlkMD-WLcplu9b6pcJ3OqxfYCUS6YhLvFgZ1hW-nDz-aHaxG-VQGxNNpTsymwTHWLMKySa4AB2znT00wQJFgcZSYp_j9nO1C4jzUckUZhuS4gJm7hVWfx6fEGeTTgLLx_Pa_L1w_svm0_V3f3H283NXeWkFmulRgtq0EJ2vXCu4z1zkxVCa9tNrQDhWjkCH2zbykGBBiEAL9PYw8Aa7qy8Jm_O7-5T_Fkgryb47GCe7QKxZCN6oZpOadYj2pxRtCnnBJPZJx9sOhrOzCkXszPnXMwpF8O4wVxw7PWjQhkCjP-G_gaBwLszALjnwUMy2fmTW6NPaL4Zo_-_wm_WWaW-</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Nantel, Sabryna</creator><creator>Sheikh-Mohamed, Salma</creator><creator>Chao, Gary Y.C.</creator><creator>Kurtesi, Alexandra</creator><creator>Hu, Queenie</creator><creator>Wood, Heidi</creator><creator>Colwill, Karen</creator><creator>Li, Zhijie</creator><creator>Liu, Ying</creator><creator>Seifried, Laurie</creator><creator>Bourdin, Benoîte</creator><creator>McGeer, Allison</creator><creator>Hardy, William R.</creator><creator>Rojas, Olga L.</creator><creator>Al-Aubodah, Tho-Alfakar</creator><creator>Liu, Zhiyang</creator><creator>Ostrowski, Mario A.</creator><creator>Brockman, Mark A.</creator><creator>Piccirillo, Ciriaco A.</creator><creator>Quach, Caroline</creator><creator>Rini, James M.</creator><creator>Gingras, Anne-Claude</creator><creator>Decaluwe, Hélène</creator><creator>Gommerman, Jennifer L.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1170-9475</orcidid><orcidid>https://orcid.org/0000-0002-8979-1659</orcidid><orcidid>https://orcid.org/0000-0002-7703-6779</orcidid><orcidid>https://orcid.org/0009-0008-0436-9055</orcidid><orcidid>https://orcid.org/0000-0001-6617-0633</orcidid><orcidid>https://orcid.org/0000-0003-4576-6168</orcidid><orcidid>https://orcid.org/0000-0002-4348-3159</orcidid><orcidid>https://orcid.org/0000-0001-6432-1426</orcidid><orcidid>https://orcid.org/0009-0008-0060-4716</orcidid></search><sort><creationdate>20240401</creationdate><title>Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity</title><author>Nantel, Sabryna ; Sheikh-Mohamed, Salma ; Chao, Gary Y.C. ; Kurtesi, Alexandra ; Hu, Queenie ; Wood, Heidi ; Colwill, Karen ; Li, Zhijie ; Liu, Ying ; Seifried, Laurie ; Bourdin, Benoîte ; McGeer, Allison ; Hardy, William R. ; Rojas, Olga L. ; Al-Aubodah, Tho-Alfakar ; Liu, Zhiyang ; Ostrowski, Mario A. ; Brockman, Mark A. ; Piccirillo, Ciriaco A. ; Quach, Caroline ; Rini, James M. ; Gingras, Anne-Claude ; Decaluwe, Hélène ; Gommerman, Jennifer L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-5dae5b623892cc8190cfa2266a8f72e2c73de1ba773b5e6e22eba7fd9eb041ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nantel, Sabryna</creatorcontrib><creatorcontrib>Sheikh-Mohamed, Salma</creatorcontrib><creatorcontrib>Chao, Gary Y.C.</creatorcontrib><creatorcontrib>Kurtesi, Alexandra</creatorcontrib><creatorcontrib>Hu, Queenie</creatorcontrib><creatorcontrib>Wood, Heidi</creatorcontrib><creatorcontrib>Colwill, Karen</creatorcontrib><creatorcontrib>Li, Zhijie</creatorcontrib><creatorcontrib>Liu, Ying</creatorcontrib><creatorcontrib>Seifried, Laurie</creatorcontrib><creatorcontrib>Bourdin, Benoîte</creatorcontrib><creatorcontrib>McGeer, Allison</creatorcontrib><creatorcontrib>Hardy, William R.</creatorcontrib><creatorcontrib>Rojas, Olga L.</creatorcontrib><creatorcontrib>Al-Aubodah, Tho-Alfakar</creatorcontrib><creatorcontrib>Liu, Zhiyang</creatorcontrib><creatorcontrib>Ostrowski, Mario A.</creatorcontrib><creatorcontrib>Brockman, Mark A.</creatorcontrib><creatorcontrib>Piccirillo, Ciriaco A.</creatorcontrib><creatorcontrib>Quach, Caroline</creatorcontrib><creatorcontrib>Rini, James M.</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Decaluwe, Hélène</creatorcontrib><creatorcontrib>Gommerman, Jennifer L.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Mucosal immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nantel, Sabryna</au><au>Sheikh-Mohamed, Salma</au><au>Chao, Gary Y.C.</au><au>Kurtesi, Alexandra</au><au>Hu, Queenie</au><au>Wood, Heidi</au><au>Colwill, Karen</au><au>Li, Zhijie</au><au>Liu, Ying</au><au>Seifried, Laurie</au><au>Bourdin, Benoîte</au><au>McGeer, Allison</au><au>Hardy, William R.</au><au>Rojas, Olga L.</au><au>Al-Aubodah, Tho-Alfakar</au><au>Liu, Zhiyang</au><au>Ostrowski, Mario A.</au><au>Brockman, Mark A.</au><au>Piccirillo, Ciriaco A.</au><au>Quach, Caroline</au><au>Rini, James M.</au><au>Gingras, Anne-Claude</au><au>Decaluwe, Hélène</au><au>Gommerman, Jennifer L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity</atitle><jtitle>Mucosal immunology</jtitle><addtitle>Mucosal Immunol</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>17</volume><issue>2</issue><spage>201</spage><epage>210</epage><pages>201-210</pages><issn>1933-0219</issn><eissn>1935-3456</eissn><abstract>[Display omitted]
Our understanding of the quality of cellular and humoral immunity conferred by COVID-19 vaccination alone versus vaccination plus SARS-CoV-2 breakthrough (BT) infection remains incomplete. While the current (2023) SARS-CoV-2 immune landscape of Canadians is complex, in late 2021 most Canadians had either just received a third dose of COVID-19 vaccine, or had received their two-dose primary series and then experienced an Omicron BT. Herein we took advantage of this coincident timing to contrast cellular and humoral immunity conferred by three doses of vaccine versus two doses plus BT. Our results show thatBT infection induces cell-mediated immune responses to variants comparable to an intramuscular vaccine booster dose. In contrast, BT subjects had higher salivary immunoglobulin (Ig)G and IgA levels against the Omicron spike and enhanced reactivity to the ancestral spike for the IgA isotype, which also reacted with SARS-CoV-1. Serumneutralizing antibody levels against the ancestral strain and the variants were also higher after BT infection. Our results support the need for the development of intranasal vaccines that could emulate the enhanced mucosal and humoral immunity induced by Omicron BT without exposing individuals to the risks associated with SARS-CoV-2 infection.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38278415</pmid><doi>10.1016/j.mucimm.2024.01.004</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1170-9475</orcidid><orcidid>https://orcid.org/0000-0002-8979-1659</orcidid><orcidid>https://orcid.org/0000-0002-7703-6779</orcidid><orcidid>https://orcid.org/0009-0008-0436-9055</orcidid><orcidid>https://orcid.org/0000-0001-6617-0633</orcidid><orcidid>https://orcid.org/0000-0003-4576-6168</orcidid><orcidid>https://orcid.org/0000-0002-4348-3159</orcidid><orcidid>https://orcid.org/0000-0001-6432-1426</orcidid><orcidid>https://orcid.org/0009-0008-0060-4716</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-0219 |
| ispartof | Mucosal immunology, 2024-04, Vol.17 (2), p.201-210 |
| issn | 1933-0219 1935-3456 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2925485609 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A31%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Omicron%20breakthrough%20infection%20versus%20monovalent%20SARS-CoV-2%20intramuscular%20booster%20reveals%20differences%20in%20mucosal%20and%20systemic%20humoral%20immunity&rft.jtitle=Mucosal%20immunology&rft.au=Nantel,%20Sabryna&rft.date=2024-04-01&rft.volume=17&rft.issue=2&rft.spage=201&rft.epage=210&rft.pages=201-210&rft.issn=1933-0219&rft.eissn=1935-3456&rft_id=info:doi/10.1016/j.mucimm.2024.01.004&rft_dat=%3Cproquest_cross%3E2925485609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2925485609&rft_id=info:pmid/38278415&rft_els_id=S1933021924000047&rfr_iscdi=true |